Skip to main content
Fig. 4 | Journal of Neuroinflammation

Fig. 4

From: RAS modulation prevents progressive cognitive impairment after experimental stroke: a randomized, blinded preclinical trial

Fig. 4

RAS modulation prevented Aβ42-mediated cytotoxicity in HBECs and C21 prevented hippocampal Aβ42 accumulation in SHRs post-stroke. a Representative 5× and 20× immunofluorescent Aβ/green-stained images of SHR hippocampus with blue/dapi nuclear staining, scale bar represents 100 and 50 μm for 5× and 20× images, respectively. b An Aβ1–42 ELISA analysis showed that animals treated with C21, for the first 7 days, had markedly lower hippocampal concentrations of Aβ1–42 at 30 days post-stroke than those treated with saline. (C21 × candesartan interaction F(1,18) = 1.30, P = 0.2719, n = 5–10 animals/group. c Cell viability (MTT conversion) was significantly reduced in cultured HBECs incubated with Aβ1–42 compared with untreated controls, under similar conditions. This cytotoxicity was prevented when cells were co-treated with candesartan and higher dose C21 (condition by Aβ/C21/candesartan group interaction F(5,89) = 5.68, P = 0.0002, n = 6–12 wells/group, error bars indicate SEM). Statistical significance for post hoc comparisons between groups using Tukey’s multiple comparison procedure are denoted by *P < 0.05 to indicate a difference from saline and #P < 0.05 to indicate a difference from all other treatment groups

Back to article page